Gwen O'DRiscoll

Gwen O'DRiscoll

Auto-generated profile, based on publicly available information

Gwen O'DRiscoll

Discovery Biology Discovery Sciences BioPharmaceuticals R&D, AstraZeneca Pepparedsleden 1 Mölndal 431 50 Sweden

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
MMMichael J. Munson
Michael J. Munson
GOGwen O’driscoll
Gwen O’driscoll
ASAndreia M. Silva
Andreia M. Silva
ELElisa Lázaro-Ibáñez
Elisa Lázaro-Ibáñez
AGAudrey Gallud
Audrey Gallud
ASAlan Sabirsh
Alan Sabirsh
RNA-based therapies have great potential to treat many undruggable human diseases. However, their efficacy, in particular for mRNA, remains hampered by poor cellular delivery and limited endosomal escape. Development and optimisation of delivery vectors, such as lipid nanoparticles (LNPs), are impeded by limited screening methods to probe the intracellular processing of LNPs in sufficient detail. We have developed a high-throughput imaging-based endosomal escape assay utilising a Galectin-9 reporter and fluorescently labelled mRNA to probe correlations between nanoparticle-mediated uptake, endosomal escape frequency, and mRNA translation. Furthermore, this assay has been integrated within a screening platform for optimisation of lipid nanoparticle formulations. We show that Galectin-9 recruitment is a robust, quantitative reporter of endosomal escape events induced by different mRNA delivery nanoparticles and small molecules. We identify nanoparticles with superior escape properties and demonstrate cell line variances in endosomal escape response, highlighting the need for fine-tuning of delivery formulations for specific applications.

22 October 2023 in Advanced Science
Verified
Journal Article
Open access
AIAlena Ivanova
Alena Ivanova
LBLukas Badertscher
Lukas Badertscher
GOGwen O'DRiscoll
Gwen O'DRiscoll
JBJoakim Bergman
Joakim Bergman
EGEuan Gordon
Euan Gordon
ELElisa Lázaro‐Ibáñez
Elisa Lázaro‐Ibáñez
Efficient and targeted delivery of therapeutic agents remains a bottleneck in modern medicine. Here, biochemical engineering approaches to advance the repurposing of extracellular vesicles (EVs) as drug delivery vehicles are explored. Targeting ligands such as the sugar GalNAc are displayed on the surface of EVs using a HaloTag‐fused to a protein anchor that is enriched on engineered EVs. These EVs are successfully targeted to human primary hepatocytes. In addition, the authors are able to decorate EVs with an antibody that recognizes a GLP1 cell surface receptor by using an Fc and Fab region binding moiety fused to an anchor protein, and they show that this improves EV targeting to cells that overexpress the receptor. The authors also use two different protein‐engineering approaches to improve the loading of Cre recombinase into the EV lumen and demonstrate that functional Cre protein is delivered into cells in the presence of chloroquine, an endosomal escape enhancer. Lastly, engineered EVs are well tolerated upon intravenous injection into mice without detectable signs of liver toxicity. Collectively, the data show that EVs can be engineered to improve cargo loading and specific cell targeting, which will aid their transformation into tailored drug delivery vehicles.

20 November 2020 in Research Square
Verified
Preprint
Open access
PDF file
MMMichael Munson
Michael Munson
GOGwen O'Driscoll
Gwen O'Driscoll
ASAndreia Silva
Andreia Silva
ELElisa Lázaro-Ibáñez
Elisa Lázaro-Ibáñez
AGAudrey Gallud
Audrey Gallud
ASAlan Sabirsh
Alan Sabirsh
RNA-based therapies have great potential to treat many undruggable human diseases. However, their efficacy, in particular for mRNA, remains hampered by poor cellular delivery and limited endosomal escape. Advances in the development and rational optimisation of delivery vectors, such as lipid nanoparticles (LNPs), are impeded by the limited availability of screening methods that probe the intracellular processing of LNPs in sufficient detail. We have developed a high-throughput imaging-based endosomal escape assay utilising a Galectin-9 reporter and fluorescently labelled mRNA to probe correlations between nanoparticle-mediated uptake, endosomal escape frequency, and mRNA translation. This assay has, furthermore, been integrated with a screening platform for nanoparticle formulation to optimise LNPs. We show that Galectin-9 recruitment is a robust, quantitative reporter of endosomal escape events induced by different mRNA delivery nanoparticles and small molecules. We also identify nanoparticles with superior escape properties and demonstrate significant cell line variances in endosomal escape response, highlighting the need for fine-tuning of delivery formulations for specific applications.